Research and Clinical Trials

COG AREN0321: Treatment of High Risk Renal (Kidney) Tumors
Brief Description  
This phase II trial is studying how well combination chemotherapy, radiation therapy, and/or surgery work in treating patients with high-risk kidney tumors
Who may be Eligible  

  • Newly diagnosed disease of 1 of the following histologic types:
    • Focal anaplastic Wilms' tumor
    • Diffuse anaplastic Wilms' tumor
    • Clear cell sarcoma of the kidney
    • Malignant rhabdoid tumor (renal or extrarenal)
    • Renal cell carcinoma
      • Clear cell
      • Papillary
      • Renal medullary
      • Oncocytoid
      • Sarcomatoid
      • Chromophobe
      • Collecting duct
      • Carcinoma associated with neuroblastoma
      • Renal cell carcinoma unclassified
  • High-risk disease
  • Stage I-IV disease
    • No stage V (bilateral) high-risk renal tumors
  • Patients with stage IV diffuse anaplastic Wilms' tumor are eligible for "window" therapy if the following criteria are met:
    • Measurable disease, defined as = 1 lesion that can be measured in 3 dimensions with the longest diameter (which may be in the cranio-caudal dimension) = 1 cm on CT scan or MRI
    • No tumors that could potentially cause life-threatening complications with tumor progression, such as tumors with intracranial or intraspinal extension
    • No tumors that could compress the airway
  • No CNS tumors
  • Age up to age 30 years
  • Not pregnant or nursing
  • No prior systemic chemotherapy or radiation therapy
  • No more than 14 days since prior surgery or biopsy unless medically contraindicated or pathological diagnosis requires special studies
  • No concurrent aprepitant
Genitourinary Cancer
IRB Number  
Principal Investigator  
Kaplan, Joel

For More Information, Contact  Lynnae  , Schwandt
Phone:  (704) 355-1188  Fax:  (704) 446-1989  
Address:1025 Morehead Medical Drive Suite 600 Charlotte, NC 28204